Frank Schnieders, CEO of Provecs, said: “With the conclusion of this agreement with BioReliance, we have moved significantly closer to the commencement of clinical trials with Immunalon. In animal studies, it has been shown capable of stimulating a strong immunological response to tumor cells.
“It holds the possibility of causing the immune system to attack and destroy tumors and their metastases. We selected BioReliance to manufacture investigational quantities of Immunalon because of their reputation for quality and reliability.”